Flightpath's R&D team is building an array of technologies against nature’s most biologically sophisticated pathogens.
Therapeutic Development Programs
Product Name | Program | Primary Pathogen | Discovery | Preclinical | IND | Phase I |
Phase II |
Phase III |
Marketed | Development Partner |
---|---|---|---|---|---|---|---|---|---|---|
FP-100 | Lyme disease | B. burgdorferi | internal | |||||||
Description: FP-100 is a novel, orally available narrow-spectrum antibiotic with activity against multiple gram-negative bacteria Ownership: Global development and commercialization rights owned by Flightpath Biosciences |
||||||||||
FP-100 | Colorectal Cancer | Fusobacterium Nucleatum | internal | |||||||
Description: FP-100 is a novel, orally available narrow-spectrum antibiotic with activity against multiple gram-negative bacteria Ownership: Global development and commercialization rights owned by Flightpath Biosciences |
||||||||||
FP-200 | Oral Health | Fusobacterium, T. denticola |
Forsyth Institute | |||||||
Description: FP-200 is a new, narrow-spectrum antibiotic with activity against multiple gram-negative bacteria responsible for local oral disease and systemic chronic illnesses. Development Partnership: Co-development agreement between Forsyth Institute and Flightpath Biosciences. Goal: to determine the impact of eliminating gram-negative bacteria but not commensal bacteria from the oral cavity. The team will also be looking at implications on downstream systemic chronic diseases (e.g. neurodegenerative disease) |
||||||||||
FP-100 | Syphilis & NTD yaws | T. pallidum, T. pallidum pertinue |
internal | |||||||
Description: FP-100 is a novel, orally available narrow-spectrum antibiotic with activity against multiple spirochetal and gram-negative bacteria Ownership: Global development and commercialization rights owned by Flightpath Biosciences |
||||||||||
FP-300 | Women's Health | Fusobacterium | internal | |||||||
Description: FP-300 is a narrow-spectrum antibiotic with activity against Fusobacterium Nucleatum Ownership: Global development and commercialization rights owned by Flightpath Biosciences |
Flightpath is seeking partners to develop agricultural and animal health applications.
Contact Us for more information